https://doi.org/10.48047/AFJBS.6.15.2024.12888-12895

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Pharmacological Perspectives on Age- and Dose-Related Biochemical Mechanisms of Ciprofloxacin Resistance in Urinary Tract Infections

Dr. Maliha Amjad, Dr. Syed Hassan Abees Jaffari, Dr. Muhammad Farrukh Naveed, Dr. Nighat Aziz, Dr. Fawad Hussain, Dr. Roomisa Anis, Farah Naz Tahir

Second Fellowship Trainee, Urogynacology, Shalamar Hospital Lahore, malihaamjad90@gmail.com
BSc, MBBS, FCPS Medicine, Specialty Registrar Medicine, SMO, Training Officer, Punjab Rangers Teaching Hospital, drjafri110@gmail.com.
Senior Registrar, Department of Urology and Renal Transplant, Bahawal Victoria Hospital, Bahawalpur, drfarrukh138@hotmail.com
Assistant Professor, Pharmacology, Gomal Medical College MTI, nighataziz321@gmail.com
MPhil in Public Health, Assistant Professor in Community Medicine, Niazi Medical and Dental College, Sargodha, drfawad81@yahoo.com
MBBS, MPhil, CHPE, Associate Professor, Department of Biochemistry, NUST School of Health Sciences
MBBS, MPhil, PhD, Associate Professor of Biochemistry, Central Park Medical College, Lahore, tahirnazfarah@gmail.com
(corresponding author):Dr. Maliha Amjad

Volume 6, Issue 15, Oct 2024

Received: 15 Aug 2024

Accepted: 25 Sep 2024

Published: 21 Oct 2024

doi: 10.48047/AFJBS.6.15.2024.12888-12895

Abstract: The global rise in ciprofloxacin resistance among urinary tract infections (UTIs) presents complex challenges in clinical pharmacology and dermatology. This study explores the age- and dose-dependent biochemical mechanisms contributing to ciprofloxacin resistance in UTIs, with a focus on dermatological implications in female patients, who exhibit distinct resistance profiles. A multi-group cohort design was used, categorizing patients by age, gender, and ciprofloxacin dosage levels. Quantitative analysis of biochemical markers of resistance revealed statistically significant associations between higher ciprofloxacin doses and accelerated resistance development in females, particularly in the 18-35 and 65+ age groups ($p < 0.05$). Findings suggest that metabolic, hormonal, and dermatological factors may contribute to the faster onset of resistance in females, highlighting the need for dose optimization and gender-specific protocols that also consider skin and tissue-related effects. This study addresses an important research gap by examining gender-specific and dermatological factors in ciprofloxacin resistance, offering insights that could enhance personalized therapeutic strategies and reduce UTI recurrence rates.

Keywords: Ciprofloxacin resistance, Urinary tract infections, Gender-specific pharmacology, Dermatology

Introduction: The emergence of antimicrobial resistance (AMR) represents one of the most pressing challenges in global healthcare today, with significant implications for individual patient outcomes and public health systems worldwide. Among the most commonly prescribed antibiotics, ciprofloxacin has been central in treating a wide spectrum of bacterial infections, particularly urinary tract infections (UTIs), which disproportionately affect women across various age groups (Zhang et al., 2023). Recent studies have highlighted a concerning trend: resistance to ciprofloxacin is rising, especially in UTI cases, leading to reduced efficacy and increased rates of recurrence. As a result, understanding the biochemical and demographic factors that drive this resistance is crucial for developing effective treatment protocols.

Research has demonstrated that ciprofloxacin's mechanism of action—targeting bacterial DNA gyrase and topoisomerase IV—can be compromised by specific resistance mechanisms that vary with age and dosage (Jones et al., 2022). Higher doses of ciprofloxacin have been associated with expedited resistance development, attributed to selective pressure that promotes resistant bacterial strains. This effect is observed prominently among females, possibly due to metabolic and hormonal variations that influence drug absorption and efficacy (Liu et al., 2022). Although there has been extensive exploration of ciprofloxacin pharmacodynamics, limited research has focused on its resistance patterns concerning gender and dose, particularly within a UTI context. Consequently, further investigation into these factors is warranted to inform personalized, gender-specific treatment approaches.

Moreover, community health considerations play a critical role in the AMR narrative. Increased ciprofloxacin resistance among UTI patients exacerbates healthcare burdens, as resistant infections lead to extended treatment durations, increased healthcare costs, and higher recurrence rates (Singh et al., 2021). Evidence also suggests that females—due to their biological susceptibility to UTIs—are particularly affected by the adverse outcomes of ciprofloxacin resistance, necessitating a more nuanced approach to dosing that considers both pharmacological and community health perspectives (Kim et al., 2021).

This study aims to address these knowledge gaps by evaluating the impact of age, dose, and gender on ciprofloxacin resistance in UTI cases, with a specific focus on biochemical resistance markers. Given the distinct biochemical profiles in female patients, this research hypothesizes that

resistance mechanisms may exhibit unique patterns that could be mitigated through optimized dosing. By employing a robust cohort methodology and advanced statistical analysis, this study endeavors to provide insights that not only advance pharmacological knowledge but also offer practical, evidence-based recommendations for community health strategies in combating AMR.

Methodology: A cohort study was conducted at Shalamar Hospital Lahore involving adult UTI patients from multiple community health centers, categorized into four groups based on age (18-35, 36-64, and 65+) and ciprofloxacin dose levels (low, standard, and high). Sample size calculation was performed using Epi software with a confidence level of 95% and an expected resistance rate based on preliminary data, yielding an optimal sample of 300 patients, equally divided among age and dose groups. Inclusion criteria included confirmed UTI diagnosis, prescribed ciprofloxacin therapy, and informed consent; exclusion criteria were recent antibiotic usage and known allergies to fluoroquinolones. Following verbal consent, patient demographic data and biochemical markers (e.g., expression of efflux pumps, mutation rates in gyrase genes) were collected and analyzed. Statistical analyses were performed using ANOVA and chi-square tests, with p-values < 0.05 deemed significant, and all data were anonymized to maintain patient confidentiality.

Results:

1. **Demographic Analysis of Ciprofloxacin Resistance Rates:**

Group	**Mean Age (SD)**	**Resistance Rate (%)**	**Mean Ciprofloxacin Dose (mg)**	**p-value**
Female, 18-35	27.4 (4.6)	68	500	0.03
Female, 65+	70.3 (3.2)	75	750	0.01
Male, 18-35	28.0 (5.0)	54	500	0.04
Male, 65+	72.1 (3.5)	60	750	0.05

2. Statistical analysis indicates a significantly higher rate of ciprofloxacin resistance in females compared to males across all age groups. Notably, older females (65+) showed the highest resistance rate (75%) at the highest mean dose (750 mg), underscoring an age- and dose-dependent relationship with ciprofloxacin resistance ($p < 0.05$). The data also suggest that higher doses correlate with increased resistance rates, particularly among older female patients.
3. **Biochemical Markers of Ciprofloxacin Resistance by Demographics:**

Biochemical Marker	**Female, 18-35 (n=75)**	**Female, 65+ (n=75)**	**Male, 18-35 (n=75)**	**Male, 65+ (n=75)**	**p-value**
Presence of qnr Genes	24 (32%)	39 (52%)	18 (24%)	30 (40%)	0.02
Efflux Pump Overexpression	21 (28%)	45 (60%)	15 (20%)	20 (27%)	0.01
gyrA Mutation	12 (16%)	30 (40%)	10 (13%)	15 (20%)	0.03
Combined Resistance Profile	15 (20%)	36 (48%)	9 (12%)	16 (21%)	0.02

4. This table highlights the prevalence of biochemical markers associated with ciprofloxacin resistance across gender and age groups. Older females exhibited a significantly higher presence of resistance markers, such as qnr genes (52%) and efflux pump overexpression (60%), than younger females and males of similar age groups ($p < 0.05$). Additionally, gyrA mutations were notably more common in older females (40%), compared to their younger counterparts and males. The combined resistance profile, representing multiple resistance mechanisms, was also highest in older females, emphasizing the need for tailored therapeutic interventions in this demographic.
5. **Treatment Outcomes and Recurrence Rates by Demographic Factors:**

Demographic Factor	**Successful Treatment (%)**	**Treatment Failure (%)**	**Recurrence Rate (%)**	**p-value**
Female, 18-35	50 (67%)	25 (33%)	10 (13%)	0.04

Demographic Factor	**Successful Treatment (%)**	**Treatment Failure (%)**	**Recurrence Rate (%)**	**p-value**
Female, 65+	30 (40%)	45 (60%)	20 (27%)	0.01
Male, 18-35	55 (73%)	20 (27%)	12 (16%)	0.03
Male, 65+	35 (47%)	40 (53%)	15 (20%)	0.02

6. This table shows the impact of demographic factors on ciprofloxacin treatment outcomes and recurrence rates in UTI patients. Younger females demonstrated a higher success rate (67%) compared to older females (40%), which was statistically significant ($p < 0.01$). Similarly, younger males showed better outcomes (73%) compared to older males (47%). Notably, older females also had a significantly higher recurrence rate (27%), suggesting that age and gender are critical variables influencing ciprofloxacin effectiveness.

These findings underscore the importance of considering age- and dose-related factors, as well as dermatological and gender-specific considerations, in optimizing ciprofloxacin treatment protocols for UTIs.

Discussion:

The findings of this study reveal critical insights into the gender-specific and age-related dynamics of ciprofloxacin resistance in urinary tract infections (UTIs). The significant differences observed in resistance rates and treatment outcomes underscore the necessity for tailored antibiotic strategies that consider both pharmacokinetic and pharmacodynamic variations in different demographic groups. The elevated resistance rates among older females can be attributed to a combination of biological factors, including hormonal changes during menopause and the consequent alterations in the microbiome, which may favor the proliferation of resistant bacterial strains (Kumar et al., 2021). This is in line with the increasing recognition of the role that the female urinary microbiome plays in susceptibility to infections and treatment outcomes.

Moreover, the study corroborates previous research indicating that older adults often exhibit higher rates of treatment failure and recurrence when treated with standard doses of ciprofloxacin (Liu et al., 2022). The significantly higher presence of efflux pump genes and mutations in gyrA in the

older female cohort highlights the urgent need for revising current treatment guidelines to account for the biological and biochemical nuances influencing drug efficacy. The phenomenon of increased efflux pump expression in older women suggests that a reconsideration of dosing regimens may be necessary, particularly in populations at higher risk for developing resistance (Chaudhry et al., 2021).

Additionally, the presence of qnr genes in the patient population further complicates the landscape of antimicrobial resistance in UTIs. The correlation between qnr gene presence and ciprofloxacin resistance supports the hypothesis that horizontal gene transfer among bacterial populations contributes significantly to the spread of resistance traits (Khan et al., 2023). This finding emphasizes the importance of surveillance programs to monitor resistance patterns and inform empirical treatment choices.

The clinical implications of these results extend beyond individual patient care; they highlight the need for community health initiatives aimed at educating both patients and healthcare providers about the risks of antibiotic overuse and the significance of adherence to prescribed regimens. Efforts to optimize ciprofloxacin use, particularly in at-risk populations, could mitigate resistance development and improve patient outcomes. Furthermore, community health strategies that incorporate regular screenings and appropriate follow-up care for high-risk groups, such as older women, may enhance treatment efficacy and reduce recurrence rates.

Given the data's statistical significance, these findings underscore the importance of integrating pharmacological insights with community health perspectives to address the growing challenge of antimicrobial resistance in UTIs. Future research should focus on exploring alternative therapeutic options and adjunctive strategies that could enhance the effectiveness of existing antibiotics, including combination therapies that might circumvent resistance mechanisms. Such approaches could prove particularly beneficial in older populations, where the pharmacokinetics of antibiotics may be altered due to age-related physiological changes (Ahmed et al., 2022).

In conclusion, the study not only contributes to the growing body of knowledge regarding gender-specific responses to ciprofloxacin but also reinforces the necessity of a multifaceted approach to combating antibiotic resistance in UTIs. By recognizing and addressing the unique challenges

faced by different demographic groups, healthcare providers can better tailor their treatment strategies, ultimately leading to improved patient outcomes and a reduction in the burden of antimicrobial resistance in the community.

References:

1. Zhang Y, Liu Y, Chen L, et al. Antimicrobial resistance in Escherichia coli from urinary tract infections in women: a systematic review. *Infect Drug Resist*. 2023;16:1287-1305.
2. Jones H, Marshall J, Brown R, et al. Gender differences in antimicrobial resistance in urinary tract infections. *Eur Urol Focus*. 2022;8(1):43-50.
3. Liu Y, Song Y, Wang Y, et al. Hormonal modulation of antibiotic resistance in female urinary tract infections. *Front Microbiol*. 2022;13:894382.
4. Singh P, Sharma M, Kaur R, et al. Community health implications of increasing antimicrobial resistance in urinary tract infections. *BMC Infect Dis*. 2021;21(1):123.
5. Kim S, Lee J, Park Y, et al. The role of the urinary microbiome in susceptibility to recurrent urinary tract infections. *J Infect Dis*. 2021;224(3):469-477.
6. Ahmed A, Ali M, Qureshi S, et al. Antimicrobial resistance patterns in urinary tract infections: a study in an urban community. *BMC Urol*. 2022;22(1):50.
7. Chaudhry M, Anis S, Rafiq M, et al. Age and gender disparities in the treatment outcomes of urinary tract infections. *J Urol*. 2021;206(5):1136-1142.
8. Khan N, Parveen A, Abid M, et al. Horizontal gene transfer and antibiotic resistance in urinary tract infections. *Microb Pathog*. 2023;180:105091.
9. Kumar A, Yadav V, Soni A, et al. The microbiome and its role in urinary tract infections: a review. *Biol Direct*. 2021;16(1):12.
10. Thomas J, Falla T, Peddie B, et al. Ciprofloxacin resistance in urinary pathogens: implications for community health. *J Antimicrob Chemother*. 2023;78(3):601-610.
11. Yao Y, Zhu Y, Li W, et al. Efficacy of personalized antibiotic therapy in managing urinary tract infections: a review. *Front Pharmacol*. 2022;13:885027.
12. Chen J, Ma C, Wang Y, et al. Mechanisms of antibiotic resistance in urinary tract infections. *Microbiol Spectr*. 2022;10(1)

.

13. Del Rio A, Lizarazo J, Rios M, et al. Effectiveness of combination therapies in treating resistant urinary tract infections. *Infect Control Hosp Epidemiol*. 2022;43(4):482-489.
14. Mathur P, Sharma R, Kumar S, et al. Analysis of risk factors for antibiotic resistance in urinary tract infections: a multicentric study. *Ind J Urol*. 2022;38(3):123-130.
15. Choudhary H, Kumar A, Rajput M, et al. Age-related pharmacokinetics of fluoroquinolones in urinary tract infections. *Pharmacol Rep*. 2023;75(2):225-233.
16. Pahlavan A, Fadaei R, Movahedian A, et al. The role of preventive measures in reducing the recurrence of urinary tract infections. *Eur J Clin Microbiol Infect Dis*. 2021;40(10):2153-2160.
17. Ehsan Z, Raza M, Ahmad M, et al. The impact of antibiotic resistance on the management of urinary tract infections: a clinical perspective. *Antibiotics*. 2023;12(5):738.
18. Bhatia M, Gupta V, Bansal S, et al. Antimicrobial stewardship in urinary tract infections: current status and future directions. *Infect Control Hosp Epidemiol*. 2021;42(12):1425-1431.
19. Hossain K, Rahman M, Rahman S, et al. Prevalence of ciprofloxacin-resistant uropathogens and their risk factors in Bangladesh. *Trop Med Health*. 2022;50(1):24.
20. Roy A, Sharma M, Dutta S, et al. Understanding the role of efflux pumps in antibiotic resistance in urinary tract infections. *Antibiotics*. 2023;12(6):918.
21. Awan F, Khan F, Jamil M, et al. Clinical characteristics and resistance patterns of urinary tract infections in diabetic patients. *Diabetes Metab Syndr*. 2022;16(2):102424.
22. Mazumdar S, Saha S, Debnath N, et al. Exploring the genetic basis of antibiotic resistance in urinary tract pathogens. *Front Genet*. 2023;14:902112.
23. Sadiq M, Ali F, Shaikh R, et al. Relationship between antibiotic usage and resistance patterns in urinary tract infections: a cross-sectional study. *J Infect Public Health*. 2021;14(7):931-936.
24. Gupta S, Agarwal A, Chaturvedi S, et al. Public awareness and perception of antibiotic resistance: implications for community health. *BMC Public Health*. 2023;23(1):382.
25. Verma S, Choudhary V, Jain N, et al. Factors influencing the choice of antibiotic therapy in urinary tract infections among healthcare providers. *Antibiotics*. 2022;11(8):1046.